Page 22 - Syndipharma

Product List IRANIAN PHARMACEUTICAL COMPANIES DIRECTORY

Type Product Strength Dosage form Indication Status

AryoSevenTM
is indicated for treatment and preven-
AryoSeven TM Registered and
Biopharmaceu- 1.2 mg 2.4 Powder and sol- tion of bleeding episodes in patients marketed
vent for solution
with Hemophilia A or B with inhibi-
tical product (Eptacog alfa mg 4.8 mg for injection tors, Acquired hemophilia, Congenital
(activated)) in Iran
factor VII deficiency, Glanzmann’s
thrombasthenia.
Solution for Altebrel is indicated for the treatment Registered and
of several autoimmune diseases like
Biopharmaceu- Altebrel 25 mg and injection in pre- Rheumatoid Arthritis, Plaque Psoria- marketed
filled syringe
tical product (Etanercept) 50 mg sis, Psoriatic Arthritis, Axial Spondy- in Iran
larthritis, Ankylosing Spondylitis and
Juvenile Idiopathic Arthritis.

Zytux™ is used for treatment of:
• Non-Hodgkin’s Lymphoma (NHL)
Zytux TM 100 mg and Concentrate • Chronic Lymphocytic Leukemia (CLL) Registered and
Biopharmaceu- for solution for • Rheumatoid Arthritis (RA) marketed
tical product
(Rituximab) 500 mg Infusion • Granulomatosis with polyangiitis in Iran
(GPA) and microscopic polyangiitis
(MPA)

AryoTrust™ is used for:
150 mg Powder and • HER2 over-expressing early breast
AryoTrust solvent* for cancer Registered and
Biopharmaceu- And concentrate • HER2 over-expressing metastatic marketed
tical product
(Trastuzumab) for solution for breast cancer in Iran
440 mg infusion • HER2 over-expressing metastatic
gastric cancer
Stivant is used in different types of
cancers such as; metastatic cancer of
100 mg Powder and colon or rectum, progressive glioblas- Registered and
Biopharmaceu- Stivant And solvent* for toma, Non-Small Cell Lung Cancer marketed
concentrate
(NSCLC), advanced or metastatic
tical product (Bevacizumab) for solution for cancer of kidney, ovarian, fallopian
400 mg infusion tube and primary peritoneal cancer, in Iran
cervical cancer and metastatic breast
cancer (off-label).

21